Form 8-K - Current report:
SEC Accession No. 0001437749-26-021707
Filing Date
2026-06-25
Accepted
2026-06-25 16:31:27
Documents
13
Period of Report
2026-06-23
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 FORM 8-K aytu20260624c_8k.htm   iXBRL 8-K 26487
6 aytu_logo.jpg GRAPHIC 7835
  Complete submission text file 0001437749-26-021707.txt   181339

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA aytu-20260623.xsd EX-101.SCH 3579
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE aytu-20260623_def.xml EX-101.DEF 11807
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE aytu-20260623_lab.xml EX-101.LAB 15858
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE aytu-20260623_pre.xml EX-101.PRE 12022
16 EXTRACTED XBRL INSTANCE DOCUMENT aytu20260624c_8k_htm.xml XML 2955
Mailing Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237
Business Address 7900 E. UNION AVENUE SUITE 920 DENVER CO 80237 (720) 437-6580
AYTU BIOPHARMA, INC (Filer) CIK: 0001385818 (see all company filings)

EIN.: 470883144 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-38247 | Film No.: 261122377
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)